[ad_1]
The Institute of Biomedical Sciences (ICBM) since Faculty of Medicine of the University of Chile in conjunction with the San jose hospital began, this Thursday, December 3, the trial of phase III of the AZD1222 vaccine against him COVID-19, which aims to summon 1,500 volunteers within the country.
The vaccine, developed by the Oxford University and the AstraZeneca Laboratory, has reported an average effectiveness of 70% so far, a percentage that would be enough to stop the pandemic.
In addition, none of the people who received this vaccine had serious symptoms of Covid-19 or hospitalization needs.
In this regard, Minister of Science, Technology, Knowledge and Innovation, Andrés Couve, stressed the importance of being part of this crusade.
“From the Ministry of Science in the month of May we assumed a commitment to design and implement 3 or 4 phase III clinical trials for the Covid-19 Vaccine in our country,” he highlighted.
“We are very happy because the Oxford / AstraZeneca trial has begun, which will allow us to better understand this vaccine and establish good links with the laboratories that develop it, thanks to the capacity and experience of the research, clinical and university community in Chile. ”He added.
Researchers highlight participation
For his part, the doctor Sergio Vargas, leader of this study and researcher of the Institute of Biomedical Sciences of the Faculty of Medicine of the University of Chile noted that “the main objective of this phase is to determine the safety, efficacy and immunogenicity of the vaccine.”
“Participating in this study should fill us with pride, since our country is actively participating in the clinical evaluations of this vaccine that will have an impact worldwide,” he added.
Although the study is extended to the entire population over 18 years of age, the collaborative agreement signed between the ICBM and Hospital San José aims, in the first instance, to offer enrollment to the health personnel of this establishment for the clinical trial of the vaccine.
“The pandemic has affected health personnel to a great extent, because they are in direct contact with the virus on a daily basis. On the one hand, our intention is to protect the first line of care and on the other, we want to contribute to the generation of knowledge ”, explained the Dr. Claudio Núñez, coordinator of Hospital San José in the study.
“During the pandemic as a hospital we have had a powerful healthcare role, today we also want to be part of the investigation,” he said.
They summon health officials
Nicole Silva, midwife at Hospital San José, she was one of the first volunteers to be inoculated.
“As health officials we have experienced firsthand the effects of this disease. I have witnessed how my colleagues give their best to care for our affected patients, so it is important to find a definitive solution, “he added.
The Director of the North Metropolitan Health Service, Guillermo Hartwig, joined these words, highlighting the importance of working together.
“The academy, the healthcare system and the private system must work together, since when we come together we can improve the quality of life of our users,” he said.
Enrollment will take place for a month, while the follow-up of volunteers will be for 2 years.
“Volunteers have to know that there is a team behind it. Security is key in the whole process, and they will have all the necessary information. There are no reasons to fear this vaccine, ”he explained. María Begoña Carroza, coordinator of dissemination and volunteers of the U. de Chile study.
To register, the volunteer must complete the form available on the websites of the Faculty of Medicine of the University of Chile, the San José Hospital or the North Metropolitan Health Service.
[ad_2]
